From Innovation to Implementation: Redefining Breast Cancer Management with Liquid Biopsy
Event Name: AMP Europe 2026
TBC
Accelerating Precision Medicine with Rapid Front-Line NGS
Event Name: AMP 2025
TBC
Laboratory Validation of Pillar’s onocoReveal Myeloid Panel on the Illumina MiSeq i100 to Deliver Rapid Front-Line NGS for Heme Malignancies
Event Name: AMP 2025
TBC
Rapid Detection of Actionable Biomarkers in Liquid Biopsy from Non-Small Cell Lung Cancer and Breast Cancer Using Targeted NGS-Based Assays
Event Name: AMP 2025
TBC
Utilizing Pillar Biosciences’ Rapid oncoReveal 4-Gene Methylation Panel to Guide PARPi Therapy in Breast Cancer Patients
Event Name: AMP 2024
TBC
The Simple Verifiation in a Molecular Pathology Lab of the FDA Approved oncoReveal CDx Pan-Cancer Solid Tumor IVD Assay
Event Name: AMP 2024
TBC
Leveraging Pillar Biosciences Targeted NGS Panels as a Rapid Front-Line Strategy to Inform and Accelerate the Delivery of Precision Medicine
Event Name: AMP 2024
TBC
Highly Accurate and Automated (RUO) NGS Assays for Efficient Localized LBx and TBx Testing in Oncology
Event Name: AMP 2023
TBC
Localized (RUO) NGS Methylation Testing to Help Inform BioPharma Clinical Trials and Improve Oncology Research
Event Name: AMP 2023
TBC